MétaCan
Menu
← Back to cohort
Record W4388725511 · doi:10.1370/afm.22.s1.4977

Improving cancer surveillance for breast, colorectal, and prostate cancer: Actionable recommendations for the BETTER Program

2023· article· en· W4388725511 on OpenAlexaboutno aff
Donna Manca, Carolina Fernandes, Aïsha Lofters, Denise Campbell‐Scherer, Melissa Shea‐Budgell, Tracy Wong, Katherine Latko, Heidi Cheung

Bibliographic record

Venuenot available
Typearticle
Languageen
FieldMedicine
TopicGlobal Cancer Incidence and Screening
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineBreast cancerCancerProstate cancerContext (archaeology)Survivorship curveColorectal cancerPopulationDiseaseOncologyFamily medicineInternal medicineEnvironmental health

Abstract

fetched live from OpenAlex

Context: Cancer and chronic disease prevention and screening (CCDPS) guidelines are not consistently applied in primary care. Cancer survivors are not only at risk of cancer recurrence but also remain at risk for other cancers and chronic diseases. Despite closer monitoring, cancer survivors achieve fewer prevention and screening goals than the general population. The BETTER program (Building on Existing Tools to Improve Chronic Disease Prevention and Screening in Primary Care) involves an evidence-based intervention provided by a healthcare professional with specialized skills in CCDPS and cancer surveillance, the Prevention Practitioner (PP). Guided by the BETTER toolkit, the PP meets with patients to assess their risk for cancer and chronic disease, and for patients with a personal history of breast, colorectal, or prostate cancer, also determines their cancer surveillance status. Objectives: To describe the: 1) evidence review process used to identify high-quality clinical practice guidelines (CPGs), 2) harmonization of cancer survivorship recommendations for breast, colorectal, and prostate cancer, and 3) identification, development, and refinement of resources and tools for inclusion in the BETTER toolkit. The BETTER toolkit will be used to inform cancer survivorship care in rural, remote, and urban primary care settings across Canada. Design: In 2017, the BETTER Program conducted a literature review of evidence-based CPGs published between 2010 and 2016. For this update, high-quality international, Canadian, and Provincial CPGs published between 2016 and 2021, focusing on breast, colorectal, or prostate cancer survivorship, and applicable to patients 40-69 years of age were identified. A Clinical Working Group reviewed the high-quality literature identified through a rigorous search, synthesized guidelines based on evidence, and updated the toolkits to inform the PP role. Setting: Rural, remote, and urban settings in Canada. Participants: Canadian researchers, clinicians, decision-makers, a patient representative. Results: Development of an updated care map for breast, colorectal, and prostate cancer surveillance that considers method of cancer treatment, long-term symptoms, and symptoms of recurrence that is tailored to the patient and adaptable to diverse practice settings. Conclusions: Synthesized and evidence-based integrated care paths can be used to assess patients’ cancer survivorship status and preferences in diverse populations in Canada.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.090
metaresearch head score (Gemma)0.232
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Other · Consensus signal: none
Teacher disagreement score0.149
Threshold uncertainty score0.474

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0900.232
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.006
Bibliometrics0.0060.006
Science and technology studies0.0040.002
Scholarly communication0.0080.008
Open science0.0080.009
Research integrity0.0110.013
Insufficient payload (model declined to judge)0.0170.005

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.067
GPT teacher head0.386
Teacher spread0.319 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same topicGlobal Cancer Incidence and Screening→French-language works237,207→